{"filings":[{"id":1693757,"accession_number":"0001493152-26-033565","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2026-07-16T21:00:40+00:00","items":["8.01"],"status":"ready","headline":"ZyVersa Therapeutics downgraded from OTCQB to OTC Pink Limited Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective July 16, 2026, ZyVersa ceased trading on OTCQB and began trading on OTC Pink Limited Market.","The move represents a downgrade in market tier, potentially reducing visibility and liquidity for the stock.","No other material events or financial updates were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1581558,"accession_number":"0001493152-26-032851","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2026-07-10T20:30:31+00:00","items":["5.02","8.01"],"status":"ready","headline":"ZyVersa Therapeutics explores cost cuts, potential going dark, and asset sales; director Park resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Min Chul Park resigned effective July 8, 2026, for personal reasons, no disagreement with company.","CEO Stephen Glover and CFO Peter Wolfe voluntarily accepted reduced compensation to preserve cash.","Company considering divesting VAR 200 or IC 100 product candidates and reducing headcount.","Company may go dark by suspending SEC reporting obligations under Rule 12h-3.","Also evaluating sale of company or assets, restructuring, or reorganization to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110143,"accession_number":"0001493152-26-008994","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ZyVersa raises $1M via convertible notes and warrants for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1M aggregate principal 10% convertible promissory notes, maturing in 12 months, with a $0.02 floor price on conversion.","Notes convertible at 80% of the lowest daily VWAP during the 10 trading days prior to conversion notice.","Series A-4 warrants exercisable six months post-issuance, expiring in 5 years; exercise price linked to qualified offering or VWAP.","Proceeds to be used for working capital; obligations guaranteed by subsidiary ZyVersa Therapeutics Operating, Inc.","Securities sold to accredited investors in a private placement under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126688,"accession_number":"0001493152-25-025966","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ZyVersa director Robert Finizio resigns from board effective Dec 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Independent director Robert G. Finizio resigned as board member, Compensation Committee chair, and Audit Committee member.","Resignation effective immediately on December 2, 2025; accepted by the Board.","Resignation was for personal reasons, not due to any disagreement with the Company on operations, policies, or practices.","No replacement has been announced for the vacated board or committee positions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126687,"accession_number":"0001493152-25-024273","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.","Net loss $19.8M vs $2.4M in Q3 2024, driven by $18.6M impairment of in-process R&D due to market cap decline.","Pre-tax loss $20.7M; R&D expense $0.4M (-16.3% YoY), G&A $1.7M (-5.1% YoY).","Raised $2.05M in Q3 2025, $4.05M YTD; company flags need for equity/debt or collaboration funding.","Lead programs: VAR 200 for FSGS (kidney) and IC 100 for cardiometabolic diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126686,"accession_number":"0001493152-25-018156","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ZyVersa CMO Pablo Guzman resigns Oct 10, 2025 to focus on family","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pablo Guzman, M.D., resigned as CMO and SVP of Medical Affairs, effective October 10, 2025.","Dr. Guzman joined ZyVersa in January 2015 with over 35 years of medical experience.","Resignation reason: personal (spend time with family and travel); no replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143470,"accession_number":"0001493152-25-013968","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq to delist ZyVersa Therapeutics common stock effective ~Sep 28, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ZyVersa on Sept 14, 2025, of delisting; Form 25 to be filed on or about Sept 18, 2025.","Stock was suspended from Nasdaq on July 17, 2025; trading on OTCQB since July 28, 2025 under symbol ZVSA.","Delisting effective ten days after Form 25 filing; company cites failure to meet minimum bid price rule.","Company's common stock will continue trading on OTCQB without disruption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143469,"accession_number":"0001641172-25-021100","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics common stock to trade on OTCQB from July 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OTCQB approval received on July 25, 2025; trading commences July 28 under ticker ZVSA.","Move to OTCQB indicates likely delisting from a senior exchange (e.g., Nasdaq).","No financial terms disclosed; company remains an SEC filer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143468,"accession_number":"0001641172-25-019856","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics receives Nasdaq delisting notice; trading suspended July 17","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel denied request to continue listing on the Nasdaq Capital Market.","Common stock trading suspended at open on July 17, 2025; plans to trade on OTC Pink Limited Market.","Delisting stems from non-compliance with minimum bid price requirement under Rule 5550(a)(2).","Company may request review by Nasdaq Council within 15 days of Panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143467,"accession_number":"0001641172-25-018403","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa enters warrant exercise inducement; expected gross proceeds ~$2.05M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing Series A-2 and A-3 warrants with $1 exercise price reduced to $0.67; holder exercises for cash.","Company issues new Series A-4 warrants to purchase 200% of exercised shares, $0.67 exercise price, 5-year term.","If all warrants exercised, gross proceeds ~$2.05 million; proceeds for working capital.","Issuance of inducement warrant shares subject to stockholder approval; registration statement to be filed by August 8, 2025.","AGP acts as financial advisor, receiving 6.5% cash fee of aggregate gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161662,"accession_number":"0001641172-25-016388","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ZyVersa enters $10M equity purchase agreement with Williamsburg Venture Holdings to fund VAR 200 clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $10M of common stock; company controls timing and amount of sales over 24-month term.","Purchase price set at 94% of lowest VWAP during three trading days after each sale clears.","2.5% commitment fee in common shares, with piggyback registration rights; no warrants or derivatives.","Funds intended to progress clinical development of Cholesterol Efflux Mediator TM VAR 200 for chronic kidney disease.","Issuance capped at 19.99% of outstanding shares unless stockholder approval is obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161661,"accession_number":"0001641172-25-014895","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ZyVersa shareholders approve up to 3.84M new shares, potentially doubling float","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing equity plan share reserve by 100,000 to 382,122 shares.","Approved issuance of up to 1,637,000 shares upon exercise of November 2024 warrants.","Approved issuance of up to 2,105,265 shares upon exercise of March 2025 warrants.","Combined potential dilution (3.84M shares) exceeds current outstanding of 3.62M shares.","All five proposals including director re-election and auditor ratification passed at June 11 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161660,"accession_number":"0001641172-25-013038","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Zyversa receives Nasdaq delisting notice for low bid price; will appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.","Ineligible for cure period due to two reverse stock splits in past two years (1:35 Dec 2023, 1:10 Apr 2024).","Unless appeal requested by June 3, 2025, securities face delisting on June 5, 2025.","Company intends to appeal and request hearing, which will stay delisting pending panel decision.","No assurance of regaining compliance with continued listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161659,"accession_number":"0001641172-25-003034","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics replaces auditor Marcum LLP with CBIZ CPAs; notes material weaknesses and going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as auditor effective April 4, 2025; CBIZ CPAs engaged April 7 after acquiring Marcum's attest practice.","Marcum's reports for FY2023 and FY2024 included an explanatory paragraph about substantial doubt on the company's ability to continue as a going concern.","Company disclosed material weaknesses in internal control over financial reporting for both FY2023 and FY2024, including lack of segregation of duties.","No disagreements on accounting principles occurred between the company and Marcum during the relevant periods.","Marcum furnished a letter agreeing with the statements; filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179770,"accession_number":"0001493152-25-009571","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","3.02","5.07","8.01","5.08","9.01"],"status":"ready","headline":"ZyVersa raises ~$2M in private placement; special meeting adjourned without quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2M from private placement of pre-funded and common warrants; pre-funded warrants priced at $0.9499.","Common warrants exercisable at $1.00/share, expire 5 years after stockholder approval.","Existing warrants from Nov 2024 amended to reduce exercise price to $1.00 per share.","Special meeting on Mar 4 lacked quorum; proposals move to 2025 annual meeting set for June 11, 2025.","Record date for 2025 annual meeting is April 15, 2025; stockholder proposals due by March 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196537,"accession_number":"0001493152-24-045371","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.","Cash at Sept 30, 2024: $0.1M; company will need additional financing on a month-to-month basis.","Phase 2a trial for VAR 200 in diabetic kidney disease expected to begin Q1 2025 with data mid-2025.","IC 100 IND submission planned for Q2 2025; Phase 1 trial in overweight subjects planned Q2/Q3 2025.","Raised ~$3.9M from Q3 2024 to present; formed new Obesity, Metabolic & Inflammatory Disease SAB."],"consensus_eps_estimate":-3.774,"consensus_eps_actual":-9.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196536,"accession_number":"0001493152-24-043754","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa raises ~$1.7M via warrant exercise inducement at $2.06/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holders exercise at reduced price of $2.06/share; gross proceeds ~$1.7M.","Company issues new Series A-2 warrants for 200% of exercised shares, exercise price $2.06, 5-year term.","Engaged A.G.P./Alliance Global Partners as financial advisor; cash fee $110,000 plus $10k expenses.","Net proceeds for working capital and general corporate purposes.","Company to file resale registration statement for new warrant shares by Dec 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196535,"accession_number":"0001493152-24-043066","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ZyVersa shareholders approve 150,000-share equity plan increase and up to 478,600 warrant shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Min Chul Park, Ph.D. as Class II director with 183,493 votes for, 13,425 withheld.","Ratified Marcum LLP as independent auditor for FY2024 with 433,670 votes for.","Approved amendment to 2022 Omnibus Equity Incentive Plan, increasing shares reserved by 150,000 to 181,795.","Approved issuance of up to 478,600 shares upon exercise of certain warrants under Nasdaq Listing Rule 5635(d).","Quorum of approx. 43% of outstanding shares (1,074,196 shares) was represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212839,"accession_number":"0001493152-24-036453","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["1.0","9.01"],"status":"ready","headline":"Zyversa Therapeutics enters $1.4M ATM equity offering with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM Agreement with A.G.P./Alliance Global Partners to sell up to $1,397,396 of common stock.","Agent receives 3.0% commission; sales at prevailing market prices under effective shelf registration.","Proceeds to be used for working capital and general corporate purposes, including R&D.","No minimum offering; Company not obligated to sell any shares under the Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212838,"accession_number":"0001493152-24-029868","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa raises ~$830k via warrant inducement at $3.46; issues 200% new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercises existing Series A/B warrants at reduced price $3.46 (from $12.50), gross proceeds ~$830k.","New Series A-1 warrants for 392k shares (5-yr term) and Series B-1 for 86.6k shares (18-mo term), all at $3.46.","New warrant shares subject to stockholder approval; meeting to be held within 90 days of closing.","Engaged A.G.P./Alliance Global Partners as financial advisor for $50k cash fee.","Company to file resale registration statement for new warrant shares by September 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231895,"accession_number":"0001493152-24-015938","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"ZyVersa Therapeutics executes 1-for-10 reverse stock split effective April 25, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-10; approved by stockholders at special meeting on April 17, 2024.","Effective at 4:01 p.m. ET on April 25; split-adjusted trading begins April 26 on Nasdaq.","Par value unchanged; new CUSIP number is 98987D 300.","Common stock continues trading under symbol ZVSA on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231894,"accession_number":"0001493152-24-015041","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["5.07","7.01"],"status":"ready","headline":"ZyVersa shareholders approve reverse stock split; board sets 1-for-10 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split at special meeting on April 17, 2024, with 2,058,182 votes for and 899,831 against.","Board of directors subsequently authorized a 1-for-10 reverse stock split ratio.","Reverse stock split effective at 4:01 p.m. ET on April 25, 2024; post-split trading begins April 26, 2024.","New CUSIP number for common stock after reverse split: 98987D 300."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250186,"accession_number":"0001493152-24-009437","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"ZyVersa receives Nasdaq reprimand for July 2023 offering; proposes reverse stock split to cure bid price deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff determined July 2023 offering required stockholder approval; issued Letter of Reprimand, no further action.","Company must cure bid price deficiency by May 3, 2024 to avoid delisting from Nasdaq.","Special stockholders meeting on April 17, 2024 to vote on reverse stock split of 1:2 to 1:50.","Company believes recent NLRP3 inhibitor data and upcoming phase 2a trial may raise stock price above $1.00, avoiding reverse split.","Board retains right to abandon reverse stock split if bid price deficiency cured by other means."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250185,"accession_number":"0001493152-24-008508","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ZyVersa Therapeutics receives approval to transfer stock listing from Nasdaq Global Market to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq approval on Feb 29, 2024 to transfer listing from Global Market to Capital Market.","Transfer effective as of open of business on March 1, 2024; ticker ZVSA unchanged.","Cures prior deficiency in minimum Market Value of Publicly Held Shares (MVPHS) requirement.","Company had 7,583,863 shares of common stock outstanding as of March 1, 2024.","Nasdaq Capital Market has similar corporate governance requirements but different listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267728,"accession_number":"0001493152-23-045948","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics dismisses Ernst & Young, appoints Marcum as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed EY as independent auditor on Dec 22, 2023; EY served from 2019 through Q3 2023 and interim period.","EY's audit reports for FY2022 and FY2021 included going-concern explanatory paragraph about substantial doubt.","No disagreements with EY; material weaknesses in internal controls over complex transactions were disclosed in 2022 10-K.","Audit Committee appointed Marcum LLP as new independent registered public accounting firm for FY2023.","No prior consultations with Marcum regarding accounting principles or audit opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267727,"accession_number":"0001493152-23-044400","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics prices $5.0M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4M shares (or pre-funded warrants in lieu) plus 4M Series A and 4M Series B warrants at combined $1.25 per unit.","Gross proceeds ~$5.0M; net proceeds for working capital and general corporate purposes.","Series A warrants $1.25 strike, 5-year term; Series B warrants $1.25 strike, 18-month term, both immediately exercisable.","Offering closed on December 11, 2023; A.G.P./Alliance Global Partners acted as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267726,"accession_number":"0001493152-23-043170","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics approves 1-for-35 reverse stock split and increases authorized shares to 251M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split 1:35 effective Dec 4, 2023 at 4:01 pm ET; adjusted trading begins Dec 5 under ZVSA.","Authorized common shares increased from 110M to 250M; total capital stock from 111M to 251M.","Split intended to meet Nasdaq's $1.00 minimum bid price requirement for continued listing.","No fractional shares will be issued; holders will receive rounding to nearest whole share.","Proportional adjustments to equity awards, warrants, and convertible securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267725,"accession_number":"0001493152-23-041884","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ZyVersa receives Nasdaq delisting determination over low bid price; hearing requested","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined to delist on Nov 16, but company requested hearing, staying delisting pending panel decision.","Stock closed at $0.10 or less for 10 consecutive days, triggering Low Priced Stocks Rule.","Company had until Dec 6, 2023 to regain $1.00 bid compliance; low price accelerated delisting.","Stockholders approved reverse stock split (1:10-1:50) at Oct 31 meeting; may be used to regain compliance.","No assurance of favorable hearing outcome or extension; stock continues trading under ZVSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267724,"accession_number":"0001493152-23-039162","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zyversa Therapeutics stockholders approve increase in authorized shares and reverse stock split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class I directors Gregory G. Freitag and James Sapirstein with ~12.1M votes each.","Ratified Ernst & Young as independent auditor for 2023 (16.5M for, 3.1M against).","Approved increase in authorized capital stock from 111M to 251M shares (13.4M for, 6.3M against).","Approved amendment to 2022 Omnibus Equity Incentive Plan, adding 4M shares (10.9M for).","Authorized reverse stock split at ratio between 1:10 and 1:50, board discretion (13.3M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284952,"accession_number":"0001493152-23-033230","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K/A","filed_at":"2023-09-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa Therapeutics raises ~$966k via warrant exercise at reduced price of $0.1357 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercised 7,121,213 shares of common stock at reduced exercise price of $0.1357 per share.","Gross proceeds of approximately $966,000; Inducement Warrants issued for the shares.","AGP acted as financial advisor, receiving 6% of net proceeds (~$58,000).","Securities issued under Section 4(a)(2) exemption; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284956,"accession_number":"0001493152-23-032553","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa Therapeutics induces warrant exercise for up to 12.1M shares; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder to exercise up to 12,121,213 existing warrants at reduced price (lower of that day's close or 5-day average) by Sep 18, 2023.","In exchange, ZyVersa issues new warrants to purchase same number of shares, exercisable at same reduced price starting 6 months after issuance for 5 years.","New warrants are unregistered, issued under Section 4(a)(2); existing warrant shares are registered.","A.G.P./Alliance Global Partners acts as financial advisor with 6% fee on gross proceeds.","Beneficial ownership blocker set at 4.99% or 9.99% per holder election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284955,"accession_number":"0001493152-23-032103","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ZyVersa receives Nasdaq notice for non-compliance with minimum MVPHS of $5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated Sept 1, 2023 for failure to meet minimum Market Value of Publicly Held Shares of $5M.","Company has 180 calendar days, until Feb 28, 2024, to regain compliance by closing MVPHS ≥$5M for 10 consecutive business days.","Failure to regain compliance could lead to delisting; company may consider transfer to Nasdaq Capital Market.","Common stock continues to trade on Nasdaq Global Market under symbol ZVSA with no immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284954,"accession_number":"0001493152-23-029441","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["5.02","5.08"],"status":"ready","headline":"ZyVersa CSO retiring Aug 18; annual meeting Oct 31, proposal deadline Aug 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO Nicholas A. LaBella, Jr. notified planned retirement effective August 18, 2023.","He is expected to remain as a member of the Scientific Advisory Board post-retirement.","Company will enter a separation agreement for compensation related to his departure.","2023 annual meeting of stockholders set for Tuesday, October 31, 2023.","Deadline for stockholder proposals and director nominations is August 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284953,"accession_number":"0001493152-23-025596","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"ZyVersa prices $2.1M public offering and extends investor lockup","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 'reasonable best efforts' public offering of ~12.7M shares/pre-funded warrants plus common warrants at $0.165/unit for ~$2.1M gross proceeds.","Common warrants exercisable at $0.165 for 5 years; pre-funded warrants exercisable at $0.0001 until exercised.","Amended April 2023 warrants to reduce exercise price from $1.00 to $0.165 and extend expiration to match new warrants.","Issued 3,044,152 lockup extension shares to certain investors in private placement to extend lockup to July 31, 2023.","Net proceeds intended for working capital and possible redemption of Series A preferred stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304755,"accession_number":"0001493152-23-020803","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ZyVersa receives Nasdaq delisting notice for $1.00 bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 9, 2023 for failing to maintain $1.00 minimum bid price over 30 consecutive business days.","Has 180 calendar days, until December 6, 2023, to regain compliance by closing at or above $1.00 for 10 consecutive business days.","If not cured, may seek a second 180-day period if it meets other listing standards and notifies intent to cure.","Failure to regain compliance could lead to delisting; company may appeal to Nasdaq hearings panel.","Company states there is no assurance it will regain compliance or secure an extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304754,"accession_number":"0001493152-23-018355","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ZyVersa Therapeutics board members Katrin Rupalla and Daniel O'Connor resign effective May 18","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Katrin Rupalla resigned to pursue opportunity that precludes board service.","Daniel O'Connor stepped down after becoming CEO of Ambrx Biopharma; no disagreement.","No successor directors announced; Chairman Stephen Glover thanked outgoing members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304753,"accession_number":"0001493152-23-016793","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ZyVersa Q1 2023 net loss $3.5M; cash only $1.3M, needs financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $1.3M as of March 31, 2023, sufficient only on month-to-month basis; company requires additional financing.","Net loss of $3.5M for Q1 2023 improved $0.2M vs Q1 2022 net loss of $3.7M, aided by $1.0M deferred tax benefit.","G&A expenses rose 53.7% to $3.5M due to insurance, marketing, and PIPE failure payments.","VAR 200 investigator-initiated trial expected Q4 2023; IND submission for IC 100 anticipated Q2 2024."],"consensus_eps_estimate":-3.774,"consensus_eps_actual":-135.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304752,"accession_number":"0001493152-23-010560","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ZyVersa reports $14.1M net loss for 2022, cash $5.9M; plans VAR 200 trial in Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue in 2022; net loss of $14.1M combined (up 75% from $8.1M in 2021).","Cash $5.9M as of Dec 31, 2022; expects to need additional financing to continue operations.","Completed business combination with Larkspur Health in Dec 2022; began trading on Nasdaq under ZVSA.","Plans investigator-initiated trial for VAR 200 in FSGS and up to two other renal indications in Q4 2023.","IC 100 preclinical program to complete in 2023; IND submission expected Q2 2024."],"consensus_eps_estimate":-3.774,"consensus_eps_actual":-135.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324290,"accession_number":"0001493152-23-007281","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZyVersa files Section 205 petition to validate charter amendment after Boxed decision uncertainty","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed petition in Delaware Chancery on March 9, 2023 seeking validation of Second Amended and Restated Certificate of Incorporation and all shares issued.","Uncertainty arose from Boxed decision questioning whether separate class vote was required for reduction of authorized shares from 220M to 110M.","Court granted expedited proceedings; final hearing set for March 29, 2023 at 11:00 a.m. ET.","Company had 9,211,922 shares outstanding as of petition date; all shares remain below authorized limits.","If validation not granted, could affect ability to raise capital and Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324289,"accession_number":"0001493152-23-006692","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ZyVersa amends license agreement with L&F Research, waives termination rights on $1.5M milestone payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LFR waives termination rights for $1M milestone payments until March 31, 2023, contingent on ZyVersa forgiving $351,579 note and paying $648,421 cash.","LFR waives termination rights for $500K milestone payment until Jan 31, 2024 or 10 days after ZyVersa raises $30M equity.","ZyVersa to forgive $351,579 promissory note from LFR as part of consideration for the waiver.","Put option agreement between ZyVersa and LFR will expire upon forgiveness of the note.","If conditions not met, waivers become void and original payment obligations reinstated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324288,"accession_number":"0001493152-23-002761","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ZyVersa grants 100,000-share option inducement to new CMO Dr. Pablo Guzman at $2.11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nonqualified stock option to purchase 100,000 shares at $2.11/share, the Jan 25, 2023 closing price.","Option has 10-year term, vests in three equal annual installments starting Jan 26, 2024, subject to continued service.","Grant approved by Compensation Committee as inducement material to Dr. Guzman's employment as CMO and SVP of Medical Affairs.","Inducement award was granted outside ZyVersa's 2022 Equity Incentive Plan under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324286,"accession_number":"0001493152-23-002764","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K/A","filed_at":"2023-01-27T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"ZyVersa amends pro forma to reflect reverse merger; adds ~$105M IPR&D asset","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma updated to forward merger (ZyVersa as VIE); ~$105M IPR&D/goodwill recorded on balance sheet.","Combined pro forma net loss: $20.96M for 9mo Sep 2022, $8.91M for FY2021.","Actual redemptions of 7.67M shares for $78.0M; 6.72M shares issued to ZyVersa equity holders.","Transaction costs $5.2M settled via $1.7M Series B preferred and $3.5M cash; deferred underwriting $3.4M settled in Series B.","Pro forma total assets $113.4M as of Sep 30, 2022, primarily from IPR&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324287,"accession_number":"0001493152-23-000844","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ZyVersa appoints Sapirstein, Freitag, and Rupalla to board post-business combination","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["ZyVersa appoints James Sapirstein (FWBI CEO), Gregory Freitag (PDSB board), and Katrin Rupalla to its board effective Jan 5, 2023.","Appointments fill three vacancies from the Dec 12, 2022 business combination with Larkspur Health Acquisition Corp.","Sapirstein to serve on Compensation & Nominating Committees; receives $40k annual retainer plus $11.5k committee fees.","Freitag to chair Audit and serve on Nominating Committee; receives $40k retainer plus $22.5k committee fees.","Rupalla to chair Nominating Committee; receives $40k retainer plus $8k; all receive option grants under 2022 Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342221,"accession_number":"0001493152-22-036510","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ZyVersa extends waiver of $1.5M milestone payments due to L&F Research to March 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment to Waiver extends L&F Research's forbearance on terminating license for non-payment of $500K IND Milestone and two $500K Phase 1/2 milestone payments.","Waiver Period extended to March 31, 2023; original deadline was January 3, 2023.","If license is terminated for other reasons or a bankruptcy event occurs before July 31, 2023, the waiver is void and payment obligations retroactively reinstated.","All other terms of the underlying License Agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342219,"accession_number":"0001493152-22-035788","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K/A","filed_at":"2022-12-16T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"ZyVersa reports Q3 2022 net loss of $3.7M, R&D spend up 473% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $3.693M for Q3 2022 vs $1.879M in Q3 2021; nine-month loss $9.445M.","R&D expenses surged to $2.334M in Q3 2022 from $0.407M, driven by $1.928M in IC100 drug manufacturing.","Cash used in operations improved to $1.078M for nine months 2022 from $4.460M in 2021.","Financing provided $1.353M via preferred stock private placement; no revenue disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342220,"accession_number":"0001493152-22-035258","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["1.01","2.01","5.06","9.01","5.02","3.02","4.01","3.01","3.03","5.03","5.01","5.05","8.01"],"status":"ready","headline":"ZyVersa Therapeutics completes de-SPAC merger with Larkspur; 99% of public shares redeemed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Larkspur merged with ZyVersa on Dec 12, 2022; name changed to ZyVersa Therapeutics, Inc. (ZVSA).","Public stockholders redeemed 7,667,029 shares (~$77.99M) at $10.17/share, leaving ~100K public shares.","PIPE investment of $8.635M via Series A Preferred and warrants at $1,000 per unit, conversion price $10.","Post-deal: 9,081,922 common shares outstanding; exchange ratio of 5.037 for Old ZyVersa shares.","Ownership: Larkspur Health LLC (16.8%), INCON Co., Ltd. (20.4%), Stephen Glover (15.1%), Daniel O'Connor (16.8%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342218,"accession_number":"0001213900-22-078742","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Larkspur Health Acquisition Corp. stockholders approve ZyVersa merger; 7.7M shares redeemed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved business combination with ZyVersa Therapeutics: 6,543,525 for, 785,791 against.","Approved charter amendments, 2022 Omnibus Incentive Plan, and Nasdaq issuance proposals.","7,667,029 shares tendered for redemption, ~76% of outstanding shares (10,029,221).","Special meeting held Dec 8, 2022; 73.08% quorum achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358991,"accession_number":"0001213900-22-040769","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2022-07-22T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Larkspur Health Acquisition Corp. announces business combination with ZyVersa Therapeutics and $7M private placement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SPAC Larkspur (LSPR) entered into Business Combination Agreement with ZyVersa Therapeutics, a clinical-stage biopharma targeting renal and inflammatory diseases.","Private placement of approximately $7.0M in Convertible Preferred shares and warrants to fund the deal, subject to additional interim financing and Nasdaq listing.","Closing deadline set for December 15, 2022; transaction requires shareholder approval and other customary conditions.","ZyVersa will survive as a wholly owned subsidiary; combined company expected to be named ZyVersa Therapeutics.","Company warrants and options assumed and converted into SPAC equity; key shareholders enter lock-up and support agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396116,"accession_number":"0001213900-22-007004","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2022-02-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Larkspur Health replaces Audit Committee Chair Raj Mehra with Gregory Skalicky due to independence determination","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raj Mehra removed as Audit Committee Chair after Board found he was not independent under SEC/Nasdaq rules.","Gregory Skalicky appointed as replacement Audit Committee Chair.","Company intends to phase in independence compliance within one-year transition period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396115,"accession_number":"0001213900-22-005920","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larkspur Health Acquisition units may separate into common stock and warrants starting Feb 10, 2022","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Units trade as LSPRU; separated common stock as LSPR, warrants as LSPRW on Nasdaq.","Separation effective February 10, 2022; holders must contact transfer agent Continental Stock Transfer.","No fractional warrants will be issued; only whole warrants will trade separately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-08T23:59:59+00:00|396115"}